Highlights from the 2026 Annual Scientific Symposium:

Pediatric Vitiligo Research Update: Current Guidelines and Best Practices for Care

Presented by Nanette Silverberg, MD, New York, NY, USA

Comparative Review of JAK Inhibitors and Conventional Immunosuppressants in Vitiligo Treatment

Presented by Davider Parsad, MD, FRCP, Chandigarh, India

Patients with Vitiligo Perspective Panel

Moderated by Alicia Roufs, Minnesota VitFriends Vitiligo Support Group

Vitiligo Advocacy: Burden of Disease

Presented by Victory Huang, Sacramento, CA, USA

Comparison of F-VASI and Vitil-lA Performance in Detecting Short-Term Changes in Facial Vitiligo

Presented by Thierry Passeron, MD, PhD, Nice, France

Afamelanotide: A Novel Promising Treatment for Vitiligo Case Studies from the Randomized CUV105 Clinical Trial

Presented by Antoine Bertolotti, MD, PhD, Reunion, France and Nairobi, Kenya

Perceived and Enacted Stigma and the Association with Clinical Characteristics,Work Productivity, Activity Impairment, and Indirect Costs in Adults with Vitiligo in the
United States and Europe

Presented by Khaled Ezzedine, MD, PhD, Paris, France

Maintenance of Repigmentation by Body Region after Ruxolitinib Cream Withd rawal: A Post Hoc Analysis of the TRuE-V Long-Term Extension Study in Vitiligo

Presented by Grace Wong, PhD, Toronto, Ontario, Canada

Characterization of Patients with Non-Segmental Vitiligo by Disease Severity in a Large Real-World Patient Cohort from U.S. Dermatology Practice

Presented by Iltefat Hamzavi, MD, FAAD, Detroit, Michigan, USA